Translation of pre-clinical studies into successful clinical trials for Alzheimer's disease

What are the roadblocks and how can they be overcome?

Avijit Banik, Richard E. Brown, James Bamburg, Debomoy Lahiri, Dheeraj Khurana, Robert P. Friedland, Wei Chen, Ying Ding, Amritpal Mudher, Ante L. Padjen, Elizabeta Mukaetova-Ladinska, Masafumi Ihara, Sudhir Srivastava, M. V Padma Srivastava, Colin L. Masters, Raj N. Kalaria, Akshay Anand

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Preclinical studies are essential for translation to disease treatments and effective use in clinical practice. An undue emphasis on single approaches to Alzheimer's disease (AD) appears to have retarded the pace of translation in the field, and there is much frustration in the public about the lack of an effective treatment. We critically reviewed past literature (1990-2014), analyzed numerous data, and discussed key issues at a consensus conference on Brain Ageing and Dementia to identify and overcome roadblocks in studies intended for translation.We highlight various factors that influence the translation of preclinical research and highlight specific preclinical strategies that have failed to demonstrate efficacy in clinical trials. The field has been hindered by the domination of the amyloid hypothesis in AD pathogenesis while the causative pathways in disease pathology are widely considered to be multifactorial. Understanding the causative events and mechanisms in the pathogenesis are equally important for translation. Greater efforts are necessary to fill in the gaps and overcome a variety of confounds in the generation, study design, testing, and evaluation of animal models and the application to future novel anti-dementia drug trials. A greater variety of potential disease mechanisms must be entertained to enhance progress.

Original languageEnglish
Pages (from-to)815-843
Number of pages29
JournalJournal of Alzheimer's Disease
Volume47
Issue number4
DOIs
StatePublished - Aug 11 2015

Fingerprint

Alzheimer Disease
Clinical Trials
Dementia
Frustration
Amyloid
Consensus
Animal Models
Pathology
Brain
Research
Pharmaceutical Preparations
Clinical Studies

Keywords

  • Alzheimer's disease
  • Animal model
  • Dementia
  • Memory disorder
  • Pre-clinical
  • Treatment

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Clinical Psychology

Cite this

Translation of pre-clinical studies into successful clinical trials for Alzheimer's disease : What are the roadblocks and how can they be overcome? / Banik, Avijit; Brown, Richard E.; Bamburg, James; Lahiri, Debomoy; Khurana, Dheeraj; Friedland, Robert P.; Chen, Wei; Ding, Ying; Mudher, Amritpal; Padjen, Ante L.; Mukaetova-Ladinska, Elizabeta; Ihara, Masafumi; Srivastava, Sudhir; Srivastava, M. V Padma; Masters, Colin L.; Kalaria, Raj N.; Anand, Akshay.

In: Journal of Alzheimer's Disease, Vol. 47, No. 4, 11.08.2015, p. 815-843.

Research output: Contribution to journalArticle

Banik, A, Brown, RE, Bamburg, J, Lahiri, D, Khurana, D, Friedland, RP, Chen, W, Ding, Y, Mudher, A, Padjen, AL, Mukaetova-Ladinska, E, Ihara, M, Srivastava, S, Srivastava, MVP, Masters, CL, Kalaria, RN & Anand, A 2015, 'Translation of pre-clinical studies into successful clinical trials for Alzheimer's disease: What are the roadblocks and how can they be overcome?', Journal of Alzheimer's Disease, vol. 47, no. 4, pp. 815-843. https://doi.org/10.3233/JAD-150136
Banik, Avijit ; Brown, Richard E. ; Bamburg, James ; Lahiri, Debomoy ; Khurana, Dheeraj ; Friedland, Robert P. ; Chen, Wei ; Ding, Ying ; Mudher, Amritpal ; Padjen, Ante L. ; Mukaetova-Ladinska, Elizabeta ; Ihara, Masafumi ; Srivastava, Sudhir ; Srivastava, M. V Padma ; Masters, Colin L. ; Kalaria, Raj N. ; Anand, Akshay. / Translation of pre-clinical studies into successful clinical trials for Alzheimer's disease : What are the roadblocks and how can they be overcome?. In: Journal of Alzheimer's Disease. 2015 ; Vol. 47, No. 4. pp. 815-843.
@article{1adc2f996f794063b4594508cabab4e9,
title = "Translation of pre-clinical studies into successful clinical trials for Alzheimer's disease: What are the roadblocks and how can they be overcome?",
abstract = "Preclinical studies are essential for translation to disease treatments and effective use in clinical practice. An undue emphasis on single approaches to Alzheimer's disease (AD) appears to have retarded the pace of translation in the field, and there is much frustration in the public about the lack of an effective treatment. We critically reviewed past literature (1990-2014), analyzed numerous data, and discussed key issues at a consensus conference on Brain Ageing and Dementia to identify and overcome roadblocks in studies intended for translation.We highlight various factors that influence the translation of preclinical research and highlight specific preclinical strategies that have failed to demonstrate efficacy in clinical trials. The field has been hindered by the domination of the amyloid hypothesis in AD pathogenesis while the causative pathways in disease pathology are widely considered to be multifactorial. Understanding the causative events and mechanisms in the pathogenesis are equally important for translation. Greater efforts are necessary to fill in the gaps and overcome a variety of confounds in the generation, study design, testing, and evaluation of animal models and the application to future novel anti-dementia drug trials. A greater variety of potential disease mechanisms must be entertained to enhance progress.",
keywords = "Alzheimer's disease, Animal model, Dementia, Memory disorder, Pre-clinical, Treatment",
author = "Avijit Banik and Brown, {Richard E.} and James Bamburg and Debomoy Lahiri and Dheeraj Khurana and Friedland, {Robert P.} and Wei Chen and Ying Ding and Amritpal Mudher and Padjen, {Ante L.} and Elizabeta Mukaetova-Ladinska and Masafumi Ihara and Sudhir Srivastava and Srivastava, {M. V Padma} and Masters, {Colin L.} and Kalaria, {Raj N.} and Akshay Anand",
year = "2015",
month = "8",
day = "11",
doi = "10.3233/JAD-150136",
language = "English",
volume = "47",
pages = "815--843",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "4",

}

TY - JOUR

T1 - Translation of pre-clinical studies into successful clinical trials for Alzheimer's disease

T2 - What are the roadblocks and how can they be overcome?

AU - Banik, Avijit

AU - Brown, Richard E.

AU - Bamburg, James

AU - Lahiri, Debomoy

AU - Khurana, Dheeraj

AU - Friedland, Robert P.

AU - Chen, Wei

AU - Ding, Ying

AU - Mudher, Amritpal

AU - Padjen, Ante L.

AU - Mukaetova-Ladinska, Elizabeta

AU - Ihara, Masafumi

AU - Srivastava, Sudhir

AU - Srivastava, M. V Padma

AU - Masters, Colin L.

AU - Kalaria, Raj N.

AU - Anand, Akshay

PY - 2015/8/11

Y1 - 2015/8/11

N2 - Preclinical studies are essential for translation to disease treatments and effective use in clinical practice. An undue emphasis on single approaches to Alzheimer's disease (AD) appears to have retarded the pace of translation in the field, and there is much frustration in the public about the lack of an effective treatment. We critically reviewed past literature (1990-2014), analyzed numerous data, and discussed key issues at a consensus conference on Brain Ageing and Dementia to identify and overcome roadblocks in studies intended for translation.We highlight various factors that influence the translation of preclinical research and highlight specific preclinical strategies that have failed to demonstrate efficacy in clinical trials. The field has been hindered by the domination of the amyloid hypothesis in AD pathogenesis while the causative pathways in disease pathology are widely considered to be multifactorial. Understanding the causative events and mechanisms in the pathogenesis are equally important for translation. Greater efforts are necessary to fill in the gaps and overcome a variety of confounds in the generation, study design, testing, and evaluation of animal models and the application to future novel anti-dementia drug trials. A greater variety of potential disease mechanisms must be entertained to enhance progress.

AB - Preclinical studies are essential for translation to disease treatments and effective use in clinical practice. An undue emphasis on single approaches to Alzheimer's disease (AD) appears to have retarded the pace of translation in the field, and there is much frustration in the public about the lack of an effective treatment. We critically reviewed past literature (1990-2014), analyzed numerous data, and discussed key issues at a consensus conference on Brain Ageing and Dementia to identify and overcome roadblocks in studies intended for translation.We highlight various factors that influence the translation of preclinical research and highlight specific preclinical strategies that have failed to demonstrate efficacy in clinical trials. The field has been hindered by the domination of the amyloid hypothesis in AD pathogenesis while the causative pathways in disease pathology are widely considered to be multifactorial. Understanding the causative events and mechanisms in the pathogenesis are equally important for translation. Greater efforts are necessary to fill in the gaps and overcome a variety of confounds in the generation, study design, testing, and evaluation of animal models and the application to future novel anti-dementia drug trials. A greater variety of potential disease mechanisms must be entertained to enhance progress.

KW - Alzheimer's disease

KW - Animal model

KW - Dementia

KW - Memory disorder

KW - Pre-clinical

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84939438777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939438777&partnerID=8YFLogxK

U2 - 10.3233/JAD-150136

DO - 10.3233/JAD-150136

M3 - Article

VL - 47

SP - 815

EP - 843

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 4

ER -